Home / Tag Archives: Diabetes complications (page 6)

Tag Archives: Diabetes complications

Early-Onset Type 2 Diabetes: Why Younger Patients Face Higher Lifetime Risk

Young adult checking blood sugar levels at home, representing early onset type 2 diabetes management and lifestyle monitoring

Early onset type 2 diabetes is no longer rare, and its rise among younger adults raises serious concerns. What happens when a chronic condition that typically appears later in life begins decades earlier? Much like starting a marathon with added weight, younger patients face a longer disease course and a …

Read More »

GLP-1s and CKD Progression: Are Anti-Inflammatory Effects Clinically Meaningful?

Medical illustration of kidneys with GLP-1 therapy pen and molecular model representing GLP-1 CKD progression and anti-inflammatory kidney effects

Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …

Read More »

GLP-1s and Microvascular Complications: Do They Change Neuropathy Trajectory?

Physician reviewing digital foot nerve imaging on tablet with GLP-1 injection pen on desk, illustrating microvascular complications and diabetic neuropathy management.

Cardiovascular outcomes often dominate discussions about GLP-1 receptor agonists, but what about nerve health? Growing interest in GLP-1 diabetic neuropathy reflects a broader shift toward understanding microvascular complications beyond heart disease. While medications such as semaglutide (Ozempic), dulaglutide (Trulicity), and liraglutide (Victoza) have proven cardiovascular benefits, their potential influence on …

Read More »

Diabetic Retinopathy in 2026: AI Screening and Early Detection Updates

AI-powered retinal camera performing diabetic retinopathy screening in a primary care clinic with detailed retinal image displayed on monitor

In 2026, diabetic retinopathy screening is entering a new era driven by artificial intelligence, tele-retinal imaging, and smarter integration into primary care workflows. Despite improved glucose monitoring and widespread use of CGM systems, diabetic retinopathy remains a leading cause of preventable blindness in adults with diabetes. So how can clinicians …

Read More »

Diabetes and Infection Risk: What Clinicians Need to Know About Prevention in a High-Risk Population

A doctor and patient wearing masks with a virus model between them, representing infection risk in diabetes care.

Why do people with diabetes face such frequent infections—and what can clinicians do to reduce the risk? With elevated blood glucose impairing immune function and circulation, patients with diabetes are more vulnerable to infections that can escalate quickly, from respiratory issues to stubborn foot ulcers. Understanding this connection is critical …

Read More »

The Expanding Landscape of Diabetes Complications: Liver Disease, Cancer, and Frailty

Illustration showing liver disease, cancer risk, brain health, and frailty in diabetes-related complications.

Early in training, many clinicians learn the classic “eye–kidney–foot” framework for recognizing and managing complications of diabetes. However, as science advances, the range of recognized consequences of diabetes—and opportunities for earlier intervention—continues to broaden. Today, the concept of diabetes complications screening must evolve to include conditions such as metabolic dysfunction–associated …

Read More »

Tackling Therapeutic Inertia: Why Providers Delay in Diabetes Care

A female doctor discusses HbA1c results with a male patient in a clinical office; the computer screen displays a chart with the message "HbA1c > 8% – ACTION NEEDED," while medical devices and a "Follow-up Needed" folder sit on the desk.

In diabetes care, “therapeutic inertia” refers to the failure to escalate or modify treatment when a patient’s glucose control is suboptimal. Even now — when newer, more effective treatments and monitoring tools are widely available — therapeutic inertia in diabetes remains a stubborn barrier. Providers often wait too long before …

Read More »